Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021

Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021

<b>Background/Objectives</b>: Meropenem–vaborbactam (MEV) and ceftazidime–avibactam (CZA) are active against “urgent threat” pathogens like carbapenem-resistant Enterobacterales (CRE). However, few studies have compared outcomes between them. <b>Methods</b>: To explore compar...

Full description

Saved in:
Bibliographic Details
Main Authors: Marya D. Zilberberg, Brian H. Nathanson, Mark A. Redell, Kate Sulham, Andrew F. Shorr
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Antibiotics
Subjects:
comparative outcomes
multidrug resistance
hospitalization
outcomes
epidemiology
Online Access:https://www.mdpi.com/2079-6382/14/1/29
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items